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Abstract
Background—Endoscopic papillectomy is increasingly used as an alternative to surgery for 
ampullary adenomas and other noninvasive ampullary lesions.
Objective—To measure short-term safety and efficacy of endoscopic papillectomy, define 
patient and lesion characteristics associated with incomplete endoscopic resection, and measure 
adenoma recurrence rates during long-term follow-up.
Design—Retrospective cohort study.
Setting—Tertiary-care academic medical center.
Patients—All patients who underwent endoscopic papillectomy for ampullary lesions between 
July 1995 and June 2012.
Intervention—Endoscopic papillectomy.
Main Outcome Measurements—Patient and lesion characteristics associated with incomplete 
endoscopic resection and ampullary adenoma-free survival analysis.
Results—We identified 182 patients who underwent endoscopic papillectomy, 134 (73.6%) 
having complete resection. Short-term adverse events occurred in 34 (18.7%). Risk factors for 
incomplete resection were jaundice at presentation (odds ratio [OR] 0.21, 95% confidence interval 
[CI] 0.07–0.69; P = .009), occult adenocarcinoma (OR 0.06, 95% CI, 0.01–0.36; P = .002), and 
intraductal involvement (OR 0.29, 95% CI, 0.11–0.75; P = .011). The en bloc resection technique 
was strongly associated with a higher rate of complete resection (OR 4.05, 95% CI, 1.71–9.59; P 
= .001). Among patients with ampullary adenoma who had complete resection (n = 107), 16 
patients (15%) developed recurrence up to 65 months after resection.
Limitations—Retrospective analysis.
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Conclusion—Jaundice at presentation, occult adenocarcinoma in the resected specimen, and 
intraductal involvement are associated with a lower rate of complete resection, whereas en bloc 
papillectomy increases the odds of complete endoscopic resection. Despite complete resection, 
recurrence was observed up to 5 years after papillectomy, confirming the need for long-term 
surveillance.
Endoscopic papillectomy is increasingly used as the first-line approach to resection for 
ampullary adenomas, having significantly lower morbidity compared with surgery in limited 
cohort studies.1 There are important knowledge gaps related to endoscopic papillectomy: (1) 
patient and lesion characteristics that are associated with the ability to achieve complete 
resection via endoscopy are unclear; (2) recurrence rates after complete endoscopic resection 
are incompletely reported2–5; (3) after tumor removal, optimal duration of endoscopic 
surveillance is unknown. The majority of ampullary lesions amenable to endoscopic 
resection are ampullary adenomas, which may originate sporadically or in the setting of 
familial adenomatous polyposis (FAP). Adenomas are considered precancerous lesions, 
having a risk of transformation to adenocarcinoma in 25% to 85% for sporadic cases and 4% 
for patients with FAP.6 Because of their malignant potential, resection of sporadic ampullary 
adenomas is recommended. However, it remains controversial as to which FAP-associated 
ampullary adenomas should be removed and which should be kept under surveillance. In 
patients with FAP, the potential risk of adenocarcinoma (ampullary or duodenal) is 
measured by the adenoma burden in the duodenum, typically quantified by using the 
Spigelman classification (stage 0-IV; depending on polyp number, size, histology, and 
severity of dysplasia).7
Surgical approaches for ampullary lesions include pancreaticoduodenectomy (ie, Whipple 
procedure) and transduodenal excision (eg, surgical ampullectomy).6 However, there is 
substantial morbidity (25%–65%) and mortality (0%–2%) associated with 
pancreaticoduodenectomy and transduodenal excision (14%–33%, 0%–9%).8–10 Although 
local surgical excision has lower morbidity compared with the Whipple procedure, limited 
data suggest that there is a higher (30%) risk of recurrence.10 Previous studies suggest that 
endoscopic resection (endoscopic papillectomy) has comparable efficacy with lower 
morbidity (18% vs 42% for surgical ampullectomy) in properly selected patients.1 Limiting 
factors for endoscopic resection as a curative intervention are incomplete removal and 
recurrence. Although previous studies demonstrated the feasibility of endoscopic 
papillectomy for ampullary adenomas, these were limited by a small number of patients, 
short follow-up duration, and limited analysis of risk factors associated with long-term 
outcomes.2–4,11,12 We sought to analyze the short-term and long-term efficacy of 
endoscopic papillectomy for the treatment of ampullary lesions, with a particular emphasis 
on risk factors associated with incomplete resection and recurrence rates during follow-up. 
Although there are subtle histopathologic differences between a lesion arising from the 
duodenal aspect of the major papilla and arising from within the ampulla, we used the terms 
ampullectomy and papillectomy interchangeably in this article.
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We conducted a retrospective cohort study of all patients who underwent attempted 
endoscopic papillectomy for known or suspected ampullary adenomas between July 1995 
and June 2012. We excluded patients with lesions deemed unresectable at the time of EUS 
or ERCP because of extensive intraductal involvement (>1 cm), invasion of the duodenal 
submucosa, or lymph node invasion. We did not attempt endoscopic papillectomy in 
patients who had undergone a previous biopsy that confirmed adenocarcinoma. Patients 
were identified by using a database containing prospectively entered data that has been IRB-
approved since 1994. We abstracted procedure reports and medical records for additional 
variables of interest. The study protocol was approved by our local institutional review 
board.
Endoscopic technique
Endoscopic papillectomy was performed by 1 of 6 endoscopists, each of whom performs 
more than 300 ERCPs per year. At the time of endoscopic resection, ERCP was routinely 
completed to (1) assess for intraductal extension and (2) identify the pancreatic orifice for 
placement of a prophylactic pancreatic duct stent. The decision to perform EUS before or at 
the time of ERCP was at the discretion of the treating endoscopist. ERCP and papillectomy 
were performed by using a side-viewing duodenoscope with a therapeutic (4.2 mm) working 
channel (Olympus Optical Co, Tokyo, Japan). In some cases, the endoscopist injected dilute 
epinephrine (1:10,000) into the submucosa to lift the lesion before resection. A needle-knife 
was used selectively to cauterize the tumor margin in an effort to create a groove for holding 
the snare in place. When possible, the entire papilla with tumor was grasped en bloc and 
resected by using standard electrocautery (Endostat HF electrosurgical generator; 
Microvasive, before November 1996 and ERBO-TOM 200 HF; ERBE USA, Marietta, Ga, 
thereafter). The power setting was 150 W, with a coagulation effect of 2 or 3 on the cutting 
edges (ERBE USA). If a piecemeal approach was used, all abnormal-appearing tissue was 
resected by using a combination of snare and forceps electrocautery. If residual tissue was 
suspected after resection, the endoscopist attempted to ablate it by using the tip of a 
polypectomy multipolar probe or argon plasma coagulation. Biliary and pancreatic 
sphincterotomies along with placement of a pancreatic duct stent (3F, 4F, or 5F pancreatic 
stent) were performed at the discretion of the treating endoscopist.
Follow-up
After the procedure, patients were discharged home unless there was a suspicion of 
postprocedure adverse event or high-risk comorbidity (eg, obstructive sleep apnea, 
congestive heart failure). The decision to perform a second endoscopy for retreatment or 
surveillance of the resection site was left to the treating endoscopist. Generally, if the 
endoscopist believed the lesion had been completely resected, a surveillance endoscopy was 
performed 6 to 12 months later. The patient underwent a repeat endoscopy sooner or was 
referred to surgery if complete resection was questionable, adenocarcinoma was identified 
on histopathologic review of the resection specimen, or stent removal was necessary.
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Medical records were abstracted for relevant patient and lesion characteristics, including a 
history of FAP and reason for clinical presentation that included incidental findings during 
upper endoscopy, screening (FAP patients), abnormal laboratory test results, and overt 
symptoms such as recent acute pancreatitis or jaundice. Ampullary adenoma refers to an 
adenoma arising from the ampulla and/or papilla. Papillectomy refers to papillary resection, 
which may or may not involve ampullary resection. Relevant lesion characteristics included 
an estimate of size by endoscopic views, histopathologic size, and the presence of 
intraductal extension by ERCP and EUS. Final histopathology included adenoma, advanced 
adenoma (defined as tubulovillous adenoma, villous adenoma, or adenoma with high-grade 
dysplasia), adenocarcinoma, and all others. We categorized the case as being a complete 
resection when a patient who underwent a surveillance endoscopy had no endoscopic 
evidence of persistently abnormal tissue, with or without surveillance biopsies, at any time 
after the index procedure. Complete resection was further subcategorized into those who 
achieved complete resection after the first endoscopy and those who required 2 or more 
endoscopies.
We measured short-term (<30 days after procedure) and long-term adverse event rates. 
Short-term adverse events including post-ERCP pancreatitis (PEP), hemorrhage, and 
perforation were defined based on consensus criteria.13 PEP was defined as new or 
worsening abdominal pain associated with new or prolonged hospitalization (at least 2 days) 
and elevation of serum amylase levels >3 times the upper limit of normal measured more 
than 24 hours after the procedure.14 ERCP-associated bleeding was defined as immediate 
bleeding during the procedure (requiring endoscopic intervention) or any time within 14 
days of the procedure; the latter was defined as ≥2 g/dL drop in hemoglobin level with 
associated clinical evidence of GI hemorrhage. Perforation was described as guidewire-
induced perforation, periampullary perforation during sphincterotomy, or luminal 
perforation anywhere else. A long-term adverse event was defined as any procedure-related 
adverse event that occurred after 30 days, including biliary and/or pancreatic orifice 
stenosis. We categorized the case as being a recurrence when a patient had recurrence of 
adenoma and/or adenocarcinoma; the analysis of recurrence was limited to the subgroup of 
patients who met our definition of complete resection.
Statistical analysis
To identify patient, lesion, and technical characteristics that were associated with achieving 
complete resection, we dichotomized the study population into those with and without 
complete resection at any time. We described dichotomous variables by using simple 
proportions with 95% confidence intervals (CI) and compared groups by using the Fisher 
exact test (for variables having <10 events) or chi-square test. We described continuous 
variables by using mean and standard deviation and compared groups by using a standard t 
test. Factors identified on univariate analysis as potentially associated with having a 
complete resection, defined as a P value < .10, were included in a forward stepwise 
conditional regression model, with ≤4 variables included at any time to avoid overfitting. In 
patients who achieved complete resection with at least 1 follow-up endoscopy, we described 
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recurrence rates as a time-to-event outcome by using the Kaplan-Meier method. Statistical 
analyses were performed by using Stata version 11.2 (StataCorp LP, College Station, Tex).
RESULTS
Short-term outcomes During the 17-year study period, we identified 223 patients referred for 
endoscopic papillectomy; 41 patients were excluded for lesions that did not involve the 
major papilla. Of the remaining 182 patients, all underwent endoscopic papillectomy for 
suspected and/or known ampullary adenoma. Incidentally, 31 patients (17%) were found to 
have a non-adenomatous lesion based on histopathologic analysis of the resected specimen 
(Fig. 1). These included inflammation and/or hyperplasia (n = 11), normal mucosa (n = 7), 
reactive atypia inconsistent with adenoma (n = 6), hamartoma (n = 3), carcinoid tumor (n = 
2), paraganglioma (n=1), and gastric heterotopia (n=1). In most of these cases, forceps 
biopsies of the papilla obtained at referring facilities suggested adenoma, prompting 
endoscopic papillectomy. In patients with adenomatous lesions confirmed by histopathology 
after papillectomy (n = 151), findings included adenoma without advanced features (n = 89), 
advanced adenoma (n = 50), and adenocarcinoma (n = 12).
Short-term (<30 days) adverse events developed in 34 of 182 patients (18.7%), including 
hemorrhage (n = 23, 12.6%), perforation (n = 3, 1.6%), pancreatitis (n = 7, 3.8%), and 
myocardial infarction (n = 1, 0.5%). Of those with hemorrhage, 1 had severe bleeding and 
required surgical intervention. Of those with pancreatitis, 1 was moderate severity. Death 
occurred in 1 patient who developed acute myocardial infarction after the procedure. Of 
those having short-term adverse events, 9 patients required hospitalization (mean length of 
stay 6.7 days, range 1–17 days) for mild pancreatitis (n = 2), moderate pancreatitis (n = 1), 
mild hemorrhage (n = 1), severe hemorrhage (n = 1), perforation (n = 2), and myocardial 
infarction (n = 1). Delayed adverse events occurred in 7 patients (3.8%), including stenosis 
of the biliary (n = 2, 1.1%), pancreatic (n = 2, 1.1%), or both (n = 3, 1.6%); all required 
extension sphincterotomy with or without orifice dilation. Of those having delayed adverse 
events, clinical presentations included acute pancreatitis (n = 2) and abdominal pain with or 
without elevated liver and pancreas chemistry results (n = 5). Biliary and pancreatic 
sphincterotomies were performed at the time of initial papillectomy in 180 patients (98.9%) 
and 157 patients (86.3%), respectively. Pancreatic stent placement was performed in 156 
patients (85.7%). En bloc and piecemeal resection were performed in 89 patients (48.9%) 
and 93 patients (51.1%), respectively.
Factors associated with complete resection
Patient and lesion characteristics were compared between those with (n = 134) and without 
(n = 48) complete resection (Table 1). Patients with complete resection had a lower mean (± 
standard deviation [SD]) age than those with incomplete resection (59.8 ± 15.3 vs 65.8 ± 
17.1; P = .02). There was no significant difference in sex (P = .68) and clinical presentation 
(P = .46) between groups. However, patients having jaundice at the time of presentation 
were more likely to have incomplete resection (27.7% vs 4.5%; P < .0001). There was no 
significant difference in tumor size by endoscopy (P = .27) or histopathology (P = .97) 
between groups, although size measurements at histology may have been inaccurate in the 
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setting of piecemeal resection. Lesions removed en bloc were significantly smaller (17.4 ± 
9.4 mm) than those removed in a piecemeal fashion (23.6 ± 13.3 mm; P = .02). The 
probability of adenocarcinoma within the resected specimen was significantly higher among 
patients with incomplete resection (20.8% vs 1.5%; P < .001).
Endoscopic variables were compared between groups (Table 2). EUS was performed at 
similar frequencies in both populations, and there was no significant difference in intraductal 
involvement as observed during EUS examination (6.4% with complete resection vs 13.3% 
with incomplete resection; P = .39). During ERCP, patients with incomplete resection had a 
significantly higher rate of intraductal extension (31.3% vs 9.0%; P = .0002). Eight patients 
(11.3%) had evidence of intraductal invasion at ERCP, which was missed at EUS. Of 
patients having jaundice at the time of presentation (n = 19), 7 patients (36.8%) had 
intraductal involvement. There was no statistically significant difference in patients who 
underwent adjuvant cautery of the residual lesion (29.1% vs 27.1%; P = .79) and biliary 
sphincterotomy (99.2% vs 100.0%; P = .55), whereas patients with complete resection had a 
higher rate of pancreatic sphincterotomy (91.7% vs 70.8%; P = .003) and pancreatic stent 
placement (91.0% vs 70.8%; P = .006) than did those with incomplete resection. Patients 
who underwent papillectomy with the en bloc technique had a significantly higher 
probability of achieving complete resection than those who did not (57.5% vs 22.9%; P < .
001). Patients who underwent papillectomy with piecemeal resection had a significantly 
larger mean (± SD) size of tumors by pathology than those who had the en bloc technique 
(20.2 ± 14.3 mm vs 13.5 ± 6.5 mm; P < .001).
When the adenoma is considered as the base outcome, the odds of achieving a complete 
resection were similar for advanced adenomas and non-adenomatous lesions but were 
significantly lower in the setting of adenocarcinoma (odds ratio [OR] 0.07, 95% CI, 0.01–
0.34) (Table 3). After we adjusted for variables potentially associated with having a 
complete resection on univariate analysis, jaundice (OR 0.21, 95% CI, 0.07–0.69; P =.009), 
adenocarcinoma (OR 0.06, 95% CI, 0.01–0.36; P= .002), and intraductal involvement (< 1 
cm) during ERCP (OR 0.29, 95% CI, 0.11–0.75; P = .011) were significantly associated 
with a lower odds of achieving complete resection. The ability to perform an en bloc 
resection was significantly associated with greater odds of achieving complete resection (OR 
4.05, 95% CI, 1.71–9.59; P = .001).
Ampullary adenoma recurrence rates
Among patients with ampullary adenomas (n = 151) who achieved complete resection (n = 
107), recurrence occurred in 16 patients (15%) as early as 7 months and as late as 65 months 
after the primary lesion was removed (Fig. 2). Patients with sporadic and FAP adenomas 
had similar risks of recurrence during follow-up (mean 22.7 months, range 1–190 months).
DISCUSSION
Because of its lower morbidity, endoscopic papillectomy is an accepted alternative to 
surgical resection in properly selected patients with non-carcinomatous ampullary lesions. 
The major concerns with endoscopic papillectomy are acute adverse events, incomplete 
resection, and lesion recurrence. Previous smaller studies established the efficacy of 
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endoscopic papillectomy in patients with ampullary adenomas.2–4,11,12 In previous reports, 
complete resection rates ranged from 77% to 93%. Fifty-five patients were reported in our 
previous study, which had complete resection of 67.3% and recurrence in about a third of 
patients.2 Risk factors associated with incomplete resection were not clarified in these 
studies. One study demonstrated that the complete resection rate was lower in patients with 
intraductal involvement of ampullary adenoma.4 The study compared endoscopic 
papillectomy for treatment of benign papillary lesions without and with intraductal growth 
(n = 75 vs n = 31).4 Complete resection was achieved in 83% without and 46% with 
intraductal growth (P < .001). Another study (21 patients evaluated over a 12-year period) 
demonstrated endoscopic failure in 74%, defined as the inability to remove the lesion 
completely regardless of the number of sessions, recurrence treated surgically, or discovery 
of carcinoma beyond the mucosal layer.5 In recent small series, endoscopic balloon dilation 
facilitated complete adenoma resection in patients with intraductal extension with a short 
follow-up period.15–17
Consistent with previous studies, we report a rate of complete endoscopic resection of 74% 
in patients with ampullary adenoma. Jaundice at the time of presentation, intraductal 
involvement at ERCP, and the presence of adenocarcinoma in the resected specimen were 
associated with significantly higher odds of incomplete resection. In patients having 1 or 
more of these characteristics, the endoscopist should be highly vigilant for residual 
pathology. In these cases, an attempt at endoscopic resection may still be reasonable, 
particularly among patients who are poor operative candidates. In fact, 2 of 12 patients with 
adenocarcinoma underwent complete endoscopic resection; in other cases, papillectomy 
confirmed the histopathologic diagnosis, where previous biopsies had been falsely negative. 
Based on our observations, en bloc resection should be used when feasible; if piecemeal 
resection is required, earlier surveillance is strongly advised. The en bloc technique provides 
a clear margin to survey for residual adenomatous tissue. It is logical that jaundice would be 
associated with incomplete resection because there is a higher correlation with 
adenocarcinoma.
To date, there are no prospective, randomized, comparative effectiveness studies of 
endoscopic papillectomy and surgical ampullectomy. Similar to our observations, previous 
studies have suggested that endoscopic papillectomy is feasible among patients with 
noninvasive lesions.1,2,4,12 Our observed PEP rate (3.8%) was low, with only 1 case of 
moderate severity, likely due to the frequent (85.7%) use of pancreatic duct stents.18 The 
impact of biliary and pancreatic sphincterotomy at the time of papillectomy on long-term 
rates of stenosis requires further investigation. It is possible, particularly with pancreatic 
sphincterotomy, that recurring stenosis of the sphincter may be increased by the use of 
electrocautery. However, we observed a low rate (3.8%) of recurring stenosis with the 
nearuniversal (98.9%) use of biliary sphincterotomy and high use (86.3%) of pancreatic 
sphincterotomy at the time of endoscopic resection. However, decades of follow-up are 
needed to define the true rate of recurring stenosis.
The optimal frequency and duration of endoscopic surveillance after endoscopic 
papillectomy are unknown. Based on our Kaplan-Meier analysis, risks of recurrence are 
similar for patients with and without FAP. Previous studies have reported adenoma 
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recurrence rates of 10% to 33%, but follow-up is highly variable.2–4,19 We observed 
recurrence in a small number of individuals even after 5 years, suggesting that long-term and 
potentially indefinite surveillance is reasonable, considering age and comorbidity. Study 
limitations include its retrospective design, variable endoscopic equipment and resection 
techniques, and limited endoscopic follow-up >5 years after the primary resection.
In conclusion, endoscopic papillectomy is a reasonable alternative to surgical resection for 
non-carcinomatous lesions of the papilla. Three negative prognostic factors including the 
presence of jaundice at the time of presentation, intraductal extension, and adenocarcinoma 
found in the resected specimen increase the likelihood of an incomplete resection. In 
patients with 1 or more of these characteristics, alternative resection strategies should be 
considered; if resection has been completed, close surveillance is warranted. When feasible, 
an en bloc approach is positively associated with complete endoscopic resection. In all 
patients with ampullary adenomas (FAP and sporadic), there is a small but measurable risk 
of recurrence up to 5 years after endoscopic resection. Therefore, longterm surveillance is 
warranted in appropriate individuals. Comparative effectiveness studies of endoscopic 
versus surgical resection are needed, as are larger populationbased studies to determine the 
optimal frequency and duration of after-resection surveillance.
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• In patients having 1 or more of 3 negative prognostic factors, alternative 
resection strategies should be considered.
• When feasible, an en bloc approach is positively associated with complete 
endoscopic resection. In all patients with ampullary adenomas (familial 
adenomatous polyposis and sporadic), there is a small but measurable risk of 
recurrence up to 5 years after endoscopic resection.
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Patient cohort: Endoscopic papillectomy between July 1995 and June 2012.
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Adenoma-free survival after endoscopic papillectomy.
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TABLE 1
Baseline characteristics of patients and ampullary lesions (n = 182)
Variable Complete resection (n = 134) Incomplete resection (n = 48) P value
Age, mean (± SD), y 59.8 ± 15.3 65.8 ± 17.1 .02
% Female, (%, 95% CI) 50.7 (42.3–59.2) 54.2 (40.1–68.3) .68
% Jaundice, (%, 95% CI) 4.5 (1.0–8.0) 27.7 (14.9–40.4) < .0001
Clinical presentation (%, 95% CI)
.46*
  Incidental finding 32.8 (24.8–40.9) 22.9 (10.8–35.0)
  FAP screening 28.4 (20.6–36.1) 25.0 (12.5–37.5)
  Abnormal laboratory test results† 8.2 (3.5–12.9) 12.5 (3.0–22.0)
  Overt symptoms‡ 26.9 (19.3–34.4) 37.5 (23.6–51.4)
  Others 3.7 (0.0–7.0) 2.1 (0.0–6.2)
Ampullary lesion
  Mean (± SD) size by endoscopy (mm) 19.8 ± 11.2 23.4 ± 14.4 .27
  Mean (± SD) size by pathology (mm) 16.6 ± 11.6 16.5 ± 10.4 .97
Histology (%, 95% CI) < .001*
  Adenoma (without advanced features) 48.9 (42.2–57.5) 45.8 (31.5–60.2)
  Advanced adenoma 29.0 (21.2–36.9) 25.0 (12.5–37.5)
  Adenocarcinoma 1.5 (0.0–3.6) 20.8 (9.1–32.5)
  Other 20.6 (13.6–27.6) 8.3 (0.4–16.3)




Elevated liver function test results or amylase or lipase levels.
‡Unexplained pancreatitis, abdominal pain, or jaundice.
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TABLE 2
Endoscopic findings and therapy (n = 182)
Variable Complete resection (n = 134) Incomplete resection (n = 48) P value
EUS done before ERCP (%, 95% CI) 40.3 (32.0–48.6) 35.4 (21.9–48.9) .55
  Intraductal involvement* 6.4 (0.0–13.4) 13.3 (0.0–30.5) .39
ERCP findings (%, 95% CI)
  Intraductal involvement 9.0 (4.1–13.8) 31.3 (18.1–44.4) .0002
  Pancreas divisum 6.9 (2.6–11.3) 10.5 (0.8–20.3) .46
Therapy (%, 95% CI)
  En bloc resection 57.5 (49.1–65.8) 22.9 (11.0–34.8) < .0001
  Adjuvant cautery 29.1 (21.4–36.8) 27.1 (14.5–39.7) .79
  Biliary sphincterotomy 99.2 (97.2–100.0) 100.0 (100.0–100.0) .55
  Pancreatic sphincterotomy 91.7 (87.0–96.4) 70.8 (58.0–83.7) .0003
  Pancreatic stent placement 91.0 (86.1–95.8) 70.8 (58.0–83.7) .0006
CI, Confidence interval.
*
EUS intraductal involvement is the proportion of patients who underwent EUS before endoscopic papillectomy.
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TABLE 3
Relative risks of complete resection based on histology
Histology
Relative risk
(%, 95% CI) P value
Adenoma (without advanced features) Base outcome N/A
Advanced adenoma 1.09 (0.48–2.45) .84
Adenocarcinoma 0.07 (0.01–0.34) .001
Other 2.32 (0.73–7.38) .154
CI, Confidence interval.
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